Simrat Randhawa
EVP, Head of R&D · Dianthus Therapeutics, Inc. /DE/
- 2025
- Sep 3, 2026
- 6
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Simrat Randhawa files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Marino Garcia - $27.96M in DNTH purchases and sales in the last 12 months
- Ryan Savitz - $14.29M in DNTH purchases and sales in the last 12 months
- Edward Carr - $5.59M in DNTH purchases and sales in the last 12 months
- Adam M. Veness - $4.63M in DNTH purchases and sales in the last 12 months
- Paula Soteropoulos - $2.25M in DNTH purchases and sales in the last 12 months
- Anne McGeorge - $845K in DNTH purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Simrat Randhawa?
Simrat Randhawa is a corporate insider, tracked as EVP, Head of R&D of Dianthus Therapeutics, Inc. /DE/ (DNTH). InsiderAlpha holds 6 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Simrat Randhawa submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Simrat Randhawa been buying or selling stock?
Recorded transactions: 0 open-market purchases and 11 open-market sales ($15.00M) across all tracked filings.
